UBS Group
INSY

UBS Group’s Insys Therapeutics, Inc. INSY Stock Holding History

UBS Group’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-34,071
Closed -$158K – 8433
2019
Q1 		$158K Buy
34,071
+7,428
+28% +$35.2K ﹤0.01% 4767
2018
Q4 		$93K Buy
26,643
+1,033
+4% +$7.18K ﹤0.01% 5604
2018
Q3 		$258K Buy
25,610
+13,591
+113% +$108K ﹤0.01% 4865
2018
Q2 		$87K Sell
12,019
-924
-7% -$6.44K ﹤0.01% 5559
2018
Q1 		$78K Buy
12,943
+8,631
+200% +$71.3K ﹤0.01% 5403
2017
Q4 		$41K Sell
4,312
-11,771
-73% -$77K ﹤0.01% 6018
2017
Q3 		$143K Buy
16,083
+9,139
+132% +$94.3K ﹤0.01% 5086
2017
Q2 		$88K Sell
6,944
-5,102
-42% -$60.4K ﹤0.01% 5256
2017
Q1 		$127K Sell
12,046
-39,126
-76% -$417K ﹤0.01% 4940
2016
Q4 		$471K Sell
51,172
-5,888
-10% -$66.5K ﹤0.01% 4165
2016
Q3 		$672K Buy
57,060
+9,965
+21% +$151K ﹤0.01% 3702
2016
Q2 		$610K Sell
47,095
-1,231
-3% -$17.9K ﹤0.01% 3755
2016
Q1 		$772K Sell
48,326
-79,014
-62% -$1.5M ﹤0.01% 3461
2015
Q4 		$3.65M Buy
127,340
+80,392
+171% +$2.23M ﹤0.01% 2237
2015
Q3 		$1.34M Sell
46,948
-2,083
-4% -$76.7K ﹤0.01% 3101
2015
Q2 		$1.76M Sell
49,031
-6,215
-11% -$194K ﹤0.01% 3100
2015
Q1 		$1.61M Buy
55,246
+3,570
+7% +$94.4K ﹤0.01% 3136
2014
Q4 		$1.09M Buy
+51,676
New +$1.02M ﹤0.01% 3509

Other funds holding INSY

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

UBS Group's INSY Position: Q2 2019 in Review

UBS Group sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 34,071 shares — an estimated $158K sold.

UBS Group first reported a position in INSY in Q4 2014 and held it in 18 quarters. The position peaked at $3.65M in Q4 2015. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

  • UBS Group reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • UBS Group sold 34,071 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $158K.
  • UBS Group first reported a position in Insys Therapeutics, Inc. in Q4 2014 and held it in 18 quarters.
  • UBS Group's Insys Therapeutics, Inc. position peaked at $3.65M in Q4 2015.
  • 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on UBS Group's 13F filing for Q2 2019, filed 14 Aug 2019.